What is Lifesci Capital’s Forecast for CRBP Q3 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Research analysts at Lifesci Capital issued their Q3 2026 EPS estimates for shares of Corbus Pharmaceuticals in a report released on Wednesday, May 13th. Lifesci Capital analyst O. Mccammon expects that the biopharmaceutical company will post earnings of ($1.12) per share for the quarter. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.87) per share.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.03.

A number of other research firms also recently issued reports on CRBP. Oppenheimer cut their price objective on shares of Corbus Pharmaceuticals from $57.00 to $54.00 and set an “outperform” rating on the stock in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Monday, April 20th. Jefferies Financial Group cut their price objective on shares of Corbus Pharmaceuticals from $36.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday. Wall Street Zen raised shares of Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Finally, Guggenheim reissued a “buy” rating and issued a $45.00 price target on shares of Corbus Pharmaceuticals in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Corbus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $42.33.

Corbus Pharmaceuticals Price Performance

CRBP opened at $11.98 on Friday. The company has a market capitalization of $221.99 million, a price-to-earnings ratio of -2.06 and a beta of 2.68. The firm’s fifty day moving average price is $9.85 and its two-hundred day moving average price is $9.63. Corbus Pharmaceuticals has a 1 year low of $6.72 and a 1 year high of $20.56.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Pale Fire Capital SE boosted its holdings in shares of Corbus Pharmaceuticals by 14.5% in the 1st quarter. Pale Fire Capital SE now owns 21,350 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 2,700 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Corbus Pharmaceuticals by 76.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 136,602 shares of the biopharmaceutical company’s stock worth $1,281,000 after buying an additional 59,248 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Corbus Pharmaceuticals in the 4th quarter worth about $462,000. Virtu Financial LLC purchased a new position in shares of Corbus Pharmaceuticals in the 4th quarter worth about $88,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Corbus Pharmaceuticals in the 4th quarter worth about $243,000. 64.64% of the stock is owned by hedge funds and other institutional investors.

Key Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: Corbus appointed pharma veteran Brent Pfeiffenberger, PharmD, MBA, to its Board of Directors, a move that can strengthen governance and add industry experience. Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
• Positive Sentiment: HC Wainwright raised earnings estimates across multiple future periods, including FY2026, FY2027, FY2028, FY2029, and FY2030, suggesting improved long-term expectations for Corbus Pharmaceuticals.
• Positive Sentiment: Lifesci Capital also issued estimates, with forecasts that were generally in line with or slightly better than prior expectations, reinforcing analyst interest in the name.
• Neutral Sentiment: Oppenheimer lowered its price target from $57 to $54 while maintaining an outperform rating, and Guggenheim reiterated a buy rating with a $45 target. The target cut is a mild headwind, but both firms still see substantial upside from current levels.
• Negative Sentiment: Despite the analyst optimism, Corbus remains unprofitable and projected to post losses in 2026 and beyond, so investors may still be treating the stock as a high-risk clinical-stage biotech.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.